These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22549269)

  • 1. Measuring altered disposition of xenobiotics in experimental models of liver disease.
    Hardwick RN; Cherrington NJ
    Curr Protoc Toxicol; 2012 May; Chapter 23():Unit 23.1.. PubMed ID: 22549269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does hepatic steatosis affect drug metabolizing enzymes in the liver?
    Buechler C; Weiss TS
    Curr Drug Metab; 2011 Jan; 12(1):24-34. PubMed ID: 21222589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.
    Fisher CD; Lickteig AJ; Augustine LM; Oude Elferink RP; Besselsen DG; Erickson RP; Cherrington NJ
    Eur J Pharmacol; 2009 Jun; 613(1-3):119-27. PubMed ID: 19358839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.
    Lickteig AJ; Fisher CD; Augustine LM; Aleksunes LM; Besselsen DG; Slitt AL; Manautou JE; Cherrington NJ
    Drug Metab Dispos; 2007 Oct; 35(10):1970-8. PubMed ID: 17640958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of xenobiotics: species differences.
    Rozman K
    Toxicol Pathol; 1988; 16(2):123-9. PubMed ID: 3055221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of phase I, II and III drug metabolism/transport by xenobiotics.
    Xu C; Li CY; Kong AN
    Arch Pharm Res; 2005 Mar; 28(3):249-68. PubMed ID: 15832810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.
    Canet MJ; Cherrington NJ
    Expert Opin Drug Metab Toxicol; 2014 Sep; 10(9):1209-19. PubMed ID: 24989624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of xenobiotic detoxification system mediated by efflux transporters].
    Suzuki H
    Yakugaku Zasshi; 1999 Nov; 119(11):822-34. PubMed ID: 10590710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics.
    Li Y; Lu J; Paxton JW
    Curr Drug Metab; 2012 Jun; 13(5):624-39. PubMed ID: 22475331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xenobiotic transporters: ascribing function from gene knockout and mutation studies.
    Klaassen CD; Lu H
    Toxicol Sci; 2008 Feb; 101(2):186-96. PubMed ID: 17698509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic stress impairs oxidative metabolism and hepatic excretion of model xenobiotic substrates in the rat.
    Pollack GM; Browne JL; Marton J; Haberer LJ
    Drug Metab Dispos; 1991; 19(1):130-4. PubMed ID: 1673385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xenobiotic transporters: another protective mechanism for chemicals.
    Klaassen CD
    Int J Toxicol; 2002; 21(1):7-12. PubMed ID: 11936902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.
    Yamazaki M; Suzuki H; Sugiyama Y
    Pharm Res; 1996 Apr; 13(4):497-513. PubMed ID: 8710738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benzo(a)pyrene disposition.
    Roth RA; Vinegar A
    Pharmacol Ther; 1990; 48(2):143-55. PubMed ID: 2293237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney.
    Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2009; 24(1):37-52. PubMed ID: 19252335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholestasis: pathophysiology and pathobiochemistry.
    Krell H; Enderle GJ
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():11-5. PubMed ID: 7483688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of xenobiotic-metabolizing enzymes in the placenta: a growing research field.
    Blanco-Castañeda R; Galaviz-Hernández C; Souto PCS; Lima VV; Giachini FR; Escudero C; Damiano AE; Barragán-Zúñiga LJ; Martínez-Aguilar G; Sosa-Macías M
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):247-263. PubMed ID: 32129110
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
    Kim MS; Wang S; Shen Z; Kochansky CJ; Strauss JR; Franklin RB; Vincent SH
    Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism, disposition, and toxicity of drugs and other xenobiotics in aquatic species.
    Guarino AM; Lech JJ
    Vet Hum Toxicol; 1986; 28 Suppl 1():38-44. PubMed ID: 3334693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transporters and xenobiotic disposition.
    Kim RB
    Toxicology; 2002 Dec; 181-182():291-7. PubMed ID: 12505328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.